References:
Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://pubmed.ncbi.nlm.nih.gov/20554713/
National Institute of Diabetes and Digestive and Kidney Diseases. (2018). Tesamorelin. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548730/
Russo, S. C., Ockene, M. W., Arpante, A. K., Johnson, J. E., Lee, H., Toribio, M., Stanley, T. L., Hadigan, C. M., Grinspoon, S. K., Erlandson, K. M., & Fourman, L. T. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://pubmed.ncbi.nlm.nih.gov/38905488/
Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://pubmed.ncbi.nlm.nih.gov/25038357/